Satvat Ali J.
SEC insider (Form 3/4/5 filer). CIK 0001621788. Director at BridgeBio Pharma, Inc. (BBIO) and 1 other issuer. 7 reported Form 4/5 transactions since Sep 2024; latest on Jun 22, 2026. Located in REDWOOD CITY, CA.
Companies Satvat Ali J. has filed insider reports for
- BridgeBio Pharma, Inc. (BBIO): Director
- Coherus Oncology, Inc. (CHRS): Director
Satvat Ali J.
CIK: 0001621788
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 22, 2026BBIO
BridgeBio Pharma, Inc.
AwardDirect4K shares- - Jun 5, 2026CHRS
Coherus Oncology, Inc.
AwardDirect30K shares- - Jun 20, 2025BBIO
BridgeBio Pharma, Inc.
AwardDirect6.6K shares- - Jun 12, 2025CHRS
Coherus Oncology, Inc.
AwardDirectStock Option (Right to Buy)
112K shares- - Dec 30, 2024BBIO
BridgeBio Pharma, Inc.
ExerciseDirect39.9K shares at avg. $16.68$665K - Dec 30, 2024BBIO
BridgeBio Pharma, Inc.
ExerciseDirect79.7K shares at avg. $10.99$876K - Dec 30, 2024BBIO
BridgeBio Pharma, Inc.
ExerciseDirect39.9K shares at avg. $26.21$1.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 22, 2026 |  BBIO BridgeBio Pharma, Inc. | Award | 3,990 | - | $0 | Direct |
| Jun 5, 2026 |  CHRS Coherus Oncology, Inc. | Award | 30,000 | - | $0 | Direct |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | Award | 6,589 | - | - | Direct |
| Jun 12, 2025 | CHRS Coherus Oncology, Inc. | Award Stock Option (Right to Buy) | 112,000 | - | - | Direct |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | Exercise | 39,851 | $16.68 | $664,715 | Direct |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | Exercise | 79,702 | $10.99 | $875,925 | Direct |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | Exercise | 39,851 | $26.21 | $1,044,495 | Direct |
1-7 of 7 transactions